Value

United

2026

Score

<h3 id="key-takeaways">Key Takeaways</h3>
<ul>
 <li>Bernstein maintains “outperform” rating on AZN with £186 price target, representing approximately 37% potential gain from £135.54 closing level</li>
 <li>The firm anticipates non-oncology products will contribute roughly 65% of AstraZeneca’s estimated 6% CAGR through 2026–2031, yet remain undervalued by markets</li>
 <li>The brokerage’s 2030 sales projection of $89.06B exceeds AstraZeneca’s $80B internal forecast by 11% and surpasses Bloomberg consensus by 8%</li>
 <li>Wainua revenue estimates for 2035 reach $4.80B at Bernstein — nearly triple the Bloomberg consensus figure of $1.80B</li>
 <li>Shares gained 3.1% on June 4, reaching $181.80; insider transactions showed $2.2M in sales over three months without corresponding purchases</li>
</ul>
AstraZeneca (AZN) shares advanced 3.1% on June 4, 2026, finishing the session at $181.80. The pharmaceutical giant’s equity has fluctuated between $134.90 and $212.71 over the past 52 weeks.
<a href="https://knockoutstocks.com/stock/AZN" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/AZN/embed" alt="AZN Stock Card"> AstraZeneca PLC, AZN </a>
In a Friday research note, Bernstein analysts reinforced their “outperform” stance on AstraZeneca. The firm maintained its £186 valuation target, contrasted with the £135.54 closing level — suggesting approximately 37% potential appreciation.
The central thesis centers on a straightforward premise: <a href="https://coincentral.com/astrazeneca-azn-stock-drops-as-breast-cancer-drug-fails-to-win-over-fda-advisors/" rel="noopener noreferrer nofollow">AstraZeneca’s</a> non-cancer therapeutic portfolio remains underappreciated by the investment community.
According to Bernstein’s analysis, this division is positioned to contribute approximately 65% of the pharmaceutical company’s anticipated 6% compound annual revenue expansion spanning 2026 through 2031. Despite this projection, the segment continues to receive insufficient recognition “in the investment debate,” analysts observe.
The brokerage’s 2030 aggregate revenue projection stands at $89.06 billion. This figure exceeds AstraZeneca’s internal risk-adjusted target of $80 billion by 11% and tops the Bloomberg consensus estimate of $82 billion by 8%. The entirety of forecasted revenue beats versus consensus from 2027 through 2035 stems from non-oncology assets.
<h3 id="wainua-represents-largest-valuation-gap">Wainua Represents Largest Valuation Gap</h3>
The most substantial discrepancy appears in Wainua, AstraZeneca’s treatment for transthyretin amyloidosis (ATTR). <a href="https://coincentral.com/boston-scientific-bsx-stock-drops-10-after-guidance-cut-at-bernstein-conference/" rel="noopener noreferrer nofollow">Bernstein’s</a> risk-adjusted 2035 revenue forecast reaches $4.80 billion — representing a 170% premium over Bloomberg consensus at $1.80 billion. AstraZeneca has issued non-risk-adjusted peak sales guidance exceeding $5 billion.
Phase 3 CARDIO-TTransform trial results are anticipated during the latter half of 2026. Dr. Sharon Barr, AstraZeneca’s head of non-oncology research and development, highlighted that ATTR cardiomyopathy diagnosis rates in the United States currently stand at merely 30% — indicating substantial untapped patient populations.
Another compound drawing attention is AZD0780, an oral PCSK9 inhibitor targeting elevated cholesterol. AstraZeneca projects peak revenues surpassing $5 billion; Bloomberg consensus estimates $2.40 billion. Bernstein forecasts $3.10 billion by 2035.
Dr. Barr emphasized that AZD0780 won’t require fasting protocols — potentially offering a competitive advantage versus Merck’s rival candidate enlicitide decanoate.
<h3 id="copd-asset-strengthens-investment-thesis">COPD Asset Strengthens Investment Thesis</h3>
Tozorakimab, AstraZeneca’s chronic obstructive pulmonary disease treatment, delivered favorable headline phase 3 results on March 27, 2026. AstraZeneca has established peak sales guidance between $3 billion and $5 billion, while Bloomberg consensus rests at $2 billion.
Within Bernstein’s optimistic scenario, analysts identify 179% upside potential to 2035 adjusted EBITA. The bearish case suggests 101% downside risk.
The currently approved product portfolio accounts for 55% of the upside projection. Ultomiris leads this category, with Bernstein’s 2035 estimate of $9.60 billion substantially exceeding consensus expectations of $6.50 billion.
Regarding valuation metrics, GuruFocus assigns AZN a GF Score of 83/100. The current P/E ratio of 27.3x trades below the five-year median of 34.2x. GF Value calculates fair value at $178.11 — marginally beneath the $181.80 trading price, indicating modest 2.1% overvaluation.
One noteworthy consideration: corporate insiders divested $2.2 million in shares during the previous three months, with zero purchasing activity documented.
Phase 3 CARDIO-TTransform data release for Wainua constitutes the next significant catalyst, scheduled for the second half of 2026.
The post <a href="https://blockonomi.com/astrazeneca-azn-stock-bernstein-identifies-37-upside-potential-in-overlooked-segment/" rel="noopener noreferrer nofollow">AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment

Table of Contents

Blockonomi

Other articles published on Jun 5, 2026

Join our free newsletter for daily crypto updates!